Sapporo Clinical Laboratory's (TSE:9776) Weak Earnings May Only Reveal A Part Of The Whole Picture

The market wasn't impressed with the soft earnings from Sapporo Clinical Laboratory Inc. (TSE:9776) recently. We did some further digging and think they have a few more reasons to be concerned beyond the statutory profit.

Check out our latest analysis for Sapporo Clinical Laboratory

How Do Unusual Items Influence Profit?

For anyone who wants to understand Sapporo Clinical Laboratory's profit beyond the statutory numbers, it's important to note that during the last twelve months statutory profit gained from JP¥83m worth of unusual items. While it's always nice to have higher profit, a large contribution from unusual items sometimes dampens our enthusiasm. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And that's as you'd expect, given these boosts are described as 'unusual'. Assuming those unusual items don't show up again in the current year, we'd thus expect profit to be weaker next year (in the absence of business growth, that is).

Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Sapporo Clinical Laboratory.

Our Take On Sapporo Clinical Laboratory's Profit Performance

Arguably, Sapporo Clinical Laboratory's statutory earnings have been distorted by unusual items boosting profit. Because of this, we think that it may be that Sapporo Clinical Laboratory's statutory profits are better than its underlying earnings power. In further bad news, its earnings per share decreased in the last year. At the end of the day, it's essential to consider more than just the factors above, if you want to understand the company properly. If you'd like to know more about Sapporo Clinical Laboratory as a business, it's important to be aware of any risks it's facing. At Simply Wall St, we found 2 warning signs for Sapporo Clinical Laboratory and we think they deserve your attention.

This note has only looked at a single factor that sheds light on the nature of Sapporo Clinical Laboratory's profit. But there are plenty of other ways to inform your opinion of a company. Some people consider a high return on equity to be a good sign of a quality business. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.